NasdaqGS:MNMDPharmaceuticals
Is MindMed (MNMD) Turning Psychedelic Policy Tailwinds Into a Durable Neuropsychiatry Advantage?
In recent coverage, Jones Trading initiated research on Mind Medicine (MindMed) with an upbeat view on its MM120 program in generalized anxiety disorder and major depressive disorder, emphasizing the company’s positioning in psychedelic drug development for neuropsychiatry.
The firm also pointed to emerging New Jersey legislation advancing regulated therapeutic access to psilocybin, underscoring how evolving state-level policy could shape MindMed’s future operating landscape.
We’ll now...